Development of IgA and IgG2 subclass deficiency after sulfasalazine therapy

scientific article published in March 1986

Development of IgA and IgG2 subclass deficiency after sulfasalazine therapy is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S0022-3476(86)80907-6
P698PubMed publication ID2869115

P2093author name stringBuckley RH
Leickly FE
P2860cites workClinical findings and intestinal immunoglobulins in children with partial IgA deficiencyQ41717057
HLA antigens in primary immunodeficiency diseasesQ42095159
Sulphasalazine induced immunodeficiencyQ42838496
Drug-induced IgA deficiency in rheumatoid arthritisQ66695052
Sulphasalazine induced selective IgA deficiency in rheumatoid arthritisQ34992897
IgA deficiency, epilepsy, and phenytoin treatmentQ39347135
Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug developmentQ40094901
P433issue3
P407language of work or nameEnglishQ1860
P921main subjectsulfasalazineQ420035
P304page(s)481-482
P577publication date1986-03-01
P1433published inThe Journal of PediatricsQ7743611
P1476titleDevelopment of IgA and IgG2 subclass deficiency after sulfasalazine therapy
P478volume108